Hansa Biopharma
ISIN: SE0002148817 | Ticker: HNSA | LEI: 549300LLEO25ZJJ3NT91
Country: Sweden
Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company. Our vision is a world where all patients with rare immunologic diseases can lead long and healthy lives. But we often see that people with rare diseases are relegated to the impossible and left to fend for themselves. That’s not the way forward. We see all patients as equal individuals with individual needs. A point of view that gives us a unique ability to deliver the most inclusive care to everyone. For us the mission is clear – we want to develop lifesaving and life altering therapies to those who need them the most. And ultimately, we can – and will – eliminate rare diseases, one patient at a time.
So how do we aim to achieve our goal?
• We partner with global scientific, medical, and patient communities to identify the most urgent needs
• We work relentlessly to meet the needs and create lifesaving treatments
• Our lead program enables kidney transplantation in difficult-to-transplant patients
2007
HeadquartersScheelevägen 22, 22363 Lund – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 1,434,496,000.00 | 1,012,808,000.00 | 1,687,406,000.00 |
| Noncurrent Assets | N/A | 41,109,000.00 | 70,466,000.00 | 82,702,000.00 |
| Property Plant And Equipment | N/A | 5,206,000.00 | 6,432,000.00 | 8,113,000.00 |
| Current Assets | N/A | 1,393,387,000.00 | 942,342,000.00 | 1,604,704,000.00 |
| Inventories | N/A | 98,000.00 | 242,000.00 | 973,000.00 |
| Current Trade Receivables | N/A | 110,000.00 | 9,712,000.00 | 42,959,000.00 |
| Current Prepayments And Current Accrued Income Other Than Current Contract Assets | N/A | N/A | 20,889,000.00 | 33,278,000.00 |
| Other Current Receivables | N/A | 9,957,000.00 | 22,538,000.00 | 31,315,000.00 |
| Cash and cash equivalents | 181,697,000.00 | 1,139,362,000.00 | 651,342,000.00 | 1,496,179,000.00 |
| Current Investments | N/A | 238,144,000.00 | 237,619,000.00 | 0.00 |
| Equity And Liabilities | N/A | 1,434,496,000.00 | 1,012,808,000.00 | 1,687,406,000.00 |
| Equity | 562,815,000.00 | 1,242,124,000.00 | 757,573,000.00 | N/A |
| Issued Capital | N/A | 45,895,000.00 | 46,335,000.00 | 55,034,000.00 |
| Retained Earnings | N/A | -1,311,671,000.00 | -1,859,953,000.00 | -2,471,087,000.00 |
| Share Premium | N/A | 2,509,458,000.00 | 2,572,925,000.00 | 3,021,541,000.00 |
| Treasury Shares | N/A | 1,421,000.00 | 1,862,000.00 | 2,590,000.00 |
| Other Reserves | N/A | -137,000.00 | 127,000.00 | 13,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 1,242,124,000.00 | 757,573,000.00 | 602,912,000.00 |
| Liabilities | N/A | 192,372,000.00 | 255,235,000.00 | 1,084,495,000.00 |
| Noncurrent Liabilities | N/A | 78,169,000.00 | 84,016,000.00 | 819,781,000.00 |
| Noncurrent Provisions | N/A | 14,426,000.00 | 7,357,000.00 | 5,192,000.00 |
| Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities | N/A | N/A | 47,020,000.00 | 29,500,000.00 |
| Deferred Tax Liabilities | N/A | 424,000.00 | 426,000.00 | 405,000.00 |
| Other Noncurrent Liabilities | N/A | N/A | 722,000.00 | 757,000.00 |
| Longterm Borrowings | N/A | N/A | 0.00 | 762,601,000.00 |
| Current Liabilities | N/A | 114,203,000.00 | 171,219,000.00 | 264,713,000.00 |
| Trade And Other Current Payables | N/A | 26,669,000.00 | 53,360,000.00 | 62,476,000.00 |
| Current Deferred Income Other Than Current Contract Liabilities | N/A | N/A | 24,961,000.00 | 40,430,000.00 |
| Accruals Classified As Current | N/A | 56,125,000.00 | 72,462,000.00 | 108,747,000.00 |
| Other Current Payables | N/A | N/A | 0.00 | 27,013,000.00 |
| Current Tax Liabilities Current | N/A | N/A | 0.00 | 604,000.00 |
| Other Current Financial Liabilities | N/A | 9,588,000.00 | 13,548,000.00 | N/A |
| Other Current Liabilities | N/A | N/A | 13,548,000.00 | 18,278,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 6,098,000.00 | 33,878,000.00 | 154,525,000.00 |
| Profit Loss From Operating Activities | -422,807,000.00 | -546,978,000.00 | -588,588,000.00 |
| Finance Income | 2,170,000.00 | 67,000.00 | 27,248,000.00 |
| Finance Costs | 257,000.00 | 1,219,000.00 | 48,639,000.00 |
| Profit Loss Before Tax | -420,893,000.00 | -548,130,000.00 | -609,979,000.00 |
| Income Tax Expense Continuing Operations | -40,000.00 | 152,000.00 | 1,155,000.00 |
| Profit (loss) | -420,853,000.00 | -548,282,000.00 | -611,134,000.00 |
| Profit Loss Attributable To Owners Of Parent | -420,853,000.00 | -548,282,000.00 | -611,134,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -420,853,000.00 | -548,282,000.00 | -611,134,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | -3,885,000.00 | -29,756,000.00 | -21,897,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -23,897,000.00 | 28,577,000.00 | 9,116,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | 106,693,000.00 | 13,668,000.00 | 67,460,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 7,666,000.00 | 8,606,000.00 | 12,054,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 275,000.00 | -6,000.00 | 34,006,000.00 |
| Adjustments For Sharebased Payments | N/A | 43,348,000.00 | 56,624,000.00 | 58,226,000.00 |
| Other Adjustments For Noncash Items | N/A | N/A | 0.00 | -20,853,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 68,000.00 | 627,000.00 | -5,101,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 105,000.00 | 143,000.00 | 1,565,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -290,274,000.00 | -481,168,000.00 | -502,733,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 294,000.00 | 2,399,000.00 | 3,331,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 182,534,000.00 | -2,399,000.00 | 229,313,000.00 |
| Proceeds From Issuing Shares | N/A | 1,070,581,000.00 | 0.00 | 396,196,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | N/A | 0.00 | 728,373,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 4,674,000.00 | 4,857,000.00 | 6,888,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 1,065,906,000.00 | -4,857,000.00 | 1,117,681,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -501,000.00 | 403,000.00 | 576,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 958,166,000.00 | -488,424,000.00 | 844,261,000.00 |
| Cash and cash equivalents | 181,697,000.00 | 1,139,362,000.00 | 651,342,000.00 | 1,496,179,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 19.07.22 | Peter Nicklin | Other | Buy | SEK 1,032,192.68 |
| 17.06.22 | Christian Kjellman | Other | Buy | SEK 345,680.85 |
| 17.06.22 | Donato Spota | Other | Sell | SEK 231,853.62 |
| 17.06.22 | Christian Kjellman | Other | Sell | SEK 200,059.98 |
| 17.06.22 | Sören Tulstrup | Other | Sell | SEK 196,210.75 |
| 17.06.22 | Sören Tulstrup | Other | Buy | SEK 196,210.75 |
| 17.06.22 | Anne Säfström Lanner | Other | Sell | SEK 134,223.15 |
| 17.06.22 | Henk Doude van Troostwijk | Other | Sell | SEK 129,524.09 |
| 17.06.22 | Sören Tulstrup | Other | Other | SEK 0.00 |
| 17.06.22 | Donato Spota | Other | Buy | SEK 0.00 |
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| Citadel Advisors LLC | 0.59% | 05.02.24 |
| GSA Capital Partners LLP | 0.69% | 05.04.24 |
| GSA Capital Partners LLP | 0.79% | 29.02.24 |
| Total | 2.07% |
SE0002148817
LEI549300LLEO25ZJJ3NT91
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.